Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published-Ahead-of-Print September 4, 2008, DOI:10.2164/jandrol.108.006015
Journal of Andrology, Vol. 30, No. 4, July/August 2009
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.108.006015

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/4/370    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guay, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guay, A. T.

Review

The Emerging Link Between Hypogonadism and Metabolic Syndrome

ANDRÉ T. GUAY

From the Center for Sexual Function/Endocrinology, Lahey Clinic, Peabody, Massachusetts, and Harvard Medical School, Boston, Massachusetts.

Correspondence to: Dr André Guay, Lahey Clinic Northshore, One Essex Center Dr, Peabody, MA 01960 (e-mail: andre.t.guay{at}lahey.org).



Abstract

The metabolic syndrome (MS) is comprised of various medical conditions that confer increased risk of diabetes and cardiovascular disease. The pathophysiologic components of MS include glucose abnormality, obesity or increased waist circumference, increased blood pressure, and hyperlipidemia. There is an increased risk of hypogonadism in men with MS and its individual components, including insulin resistance, considered by some to be at the core of MS. Hypogonadism may even predict MS. These factors are interwoven and impact overall health, including sexual dysfunction. One interesting and important question is whether treating hypogonadism with testosterone replacement will ameliorate the pathological components of MS.

     Key words: Low testosterone, insulin resistance, cardiovascular risk, obesity




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Sonmez, C. Haymana, E. Bolu, A. Aydogdu, S. Tapan, M. Serdar, B. Altun, C. Barcin, A. Taslipinar, C. Meric, et al.
Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism
Eur. J. Endocrinol., May 1, 2011; 164(5): 759 - 764.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The American Society of Andrology.